European Federation of Allergy and Airways Diseases Patients' Associations

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
>
Registration as it was on 20 May 2022
How to read and use this data card.
Download this datacard

Overview

Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

Lobbying Costs

None declared

Financial year: Jan 2021 - Dec 2021

Lobbyists (Full time equivalent)

3 Fte (5)

Lobbyists with EP accreditation

0

High-level Commission meetings

1

Lobbying Costs over the years

  • Info

    European Federation of Allergy and Airways Diseases Patients' Associations   (EFA)

    EU Transparency Register

    28473847513-94 First registered on 20 Dec 2011

    Goals / Remit

    The European Federation of Allergies and Airways Diseases Patients' Associations (EFA) is the European voice for over 200 million people living with allergies and airway diseases. We bring together 46 national associations from 25 countries and channel their knowledge and demands to European institutions. We connect stakeholders to ignite change and bridge the gaps between a wide range of policy issues to support more effective and comprehensive strategies – strategies that address the needs of our community. We strive to achieve greater patient participation in decision-making at local, national and European levels.
    We represent all patients and people whose lives are, could be or will be affected by allergies and airway diseases. We collect and share their stories to inform policymakers, stakeholders and the wider public about the impact these conditions have on individuals and society. Our activities and projects aim to raise awareness and improve patients’ Quality of Life.

    Main EU files targeted

    Public health: tobacco and smoking, health inequalities air quality, health emergencies and crisis preparedness
    Environment: indoor and ambient air quality, chemicals
    Climate change: adaptation, mitigation, green-house gases, F-Gases, aeroallergens (pollen), biodiversity
    Food: food information (allergen labelling), packaging, Farm-to-Fork Strategy, pesticides, biocides
    Health systems: medicines, vaccines, medical devices, clinical trials, Health Technology Assessment
    Digitalisation: digital health, big data, artificial intelligence
    Research agenda

    Address

    Head Office
    Rue du Congrès, 35
    Bruxelles 1000
    BELGIUM
    EU Office
    Rue du Congrès, 35
    Bruxelles 1000
    BELGIUM

    Website

  • People

    Total lobbyists declared

    5

    Employment timeLobbyists
    100%2
    50%1
    25%2

    Lobbyists (Full time equivalent)

    3

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 08 Dec 2022

    Name Start date End Date
    Ms Isabel PROANO GOMEZ 30 Jan 2020 29 Jan 2021
    Mr Panagiotis Minos CHASLARIDIS 30 Jan 2020 29 Jan 2021
    Mr Panagiotis Minos CHASLARIDIS 07 Mar 2019 28 Feb 2020
    Ms Isabel PROANO GOMEZ 20 Sep 2018 19 Sep 2019
    Ms Caroline Heilpern 20 Sep 2018 19 Sep 2019
    Ms Roberta SAVLI 20 Mar 2017 28 Feb 2018
    Ms Daniela Morghenti 10 Oct 2016 30 Sep 2017
    Ms Roberta SAVLI 04 Feb 2016 02 Feb 2017
    Ms Jelena Malinina 31 Mar 2015 27 Mar 2016
    Ms Roberta SAVLI 18 Feb 2015 16 Feb 2016
    Ms Roberta SAVLI 05 Feb 2014 03 Feb 2015
    Mrs Roberta SAVLI 05 Feb 2014 03 Feb 2015
    Mrs Roberta SAVLI 02 Feb 2013 31 Jan 2014
    Mrs Roberta SAVLI 23 Jan 2012 31 Dec 2012

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Non-governmental organisations, platforms and networks and similar

  • Networking

    Affiliation

    EFA has full membership with patient organisations such as:
    - the European Patients’ Forum (EPF), the umbrella association of patients’ organisation at the European level
    - the Global Asthma and Allergy Patient Platform (GA²P²)
    - the International Alliance of Dermatology Patients Organisations (IADPO – Global Skin)
    - the European Lung Health Group (ELHG)

    Medical organisations such as:
    - the International Primary Care Respiratory Group (IPCRG), as an associate Member
    - the European Lung Foundation (ELF) as member of the Patient Advisory Committee
    - the Global Alliance against Chronic Respiratory Diseases (GARD) as founding member
    - the Global Allergy and Asthma European Network (GA²LEN) and International Coalition of COPD Organisations (ICC)

    Public health organisations such as:
    - the Health and Environment Alliance (HEAL)
    - the European Network for Smoking and Tobacco Prevention (ENSP) as an associate Member
    - the Patient Access Partnership (PACT)
    - the EU4Health Civil Society Alliance (EU4Health CSA)

    In its daily activities, EFA is constantly in contact with other key stakeholders working in Brussels in the field of public health and environment.

    Furthermore, EFA has a wide network of contacts and other stakeholders:
    - the European Academy of Allergy and Clinical Immunology (EAACI), in which EFA is Member of the Patients Organisations Committee
    - the European Respiratory Society (ERS), in which EFA is Member of the Patient Advisory Groups on Asthma and COVID-19
    - the Global Initiative for Asthma (GINA), as GINA advocates
    - the Global Initiative for Chronic Obstructive Lung Disease (GOLD)
    - the Pharmaceutical Group of the European Union (PGEU)
    - the European Hospital and Healthcare Federation (HOPE)
    - the Allergic Rhinitis and its Impact on Asthma (ARIA)

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Does not represent commercial interests

    Closed financial year

    Jan 2021 - Dec 2021

    Lobbying costs for closed financial year

    Since 20 September 2021 self-declared 'non-commercial organisations' are no longer required to provide a lobby budget. See above timeline for this registrant's historical lobby budget.

    Total organisational budget in closed year

    1,047,567€

    Major funding types in closed year

    EU funding, Donations, Member's contribution, Grants

    Major contributions in closed year

    None declared

    Other financial info

    https://www.efanet.org/annual-report/2021/financials/transparency-and-acknowledgements
    Total budget (2021): 1,047,567 €:
    - public financing: 16,830 € (EU project grants under Horizon 2020)
    - from other sources: 450,000 €
    - member fees: 14,000 €
    - grants for EFA projects: 835,238 €
    - honoraria for advisors: 5,660 €

    Operating programme

    Membership fees
    EUR 14,000
    Membership fees 14,000 € 1,34%

    Grants
    EUR 450,000
    Abbvie 30,000 € 7% 2,88%
    Aimmune 30,000 € 7% 2,88%
    Astra Zeneca 30,000 € 7% 2,88%
    Boehringer Ingelheim 30,000 € 7% 2,88%
    Chiesi 30,000 € 7% 2,88%
    DBV Technologies 30,000 € 7% 2,88%
    GSK 30,000 € 7% 2,88%
    LEO Pharma 30,000 € 7% 2,88%
    MSD 30,000 € 7% 2,88%
    Novartis 30,000 € 7% 2,88%
    OM Vifor Pharma 30,000 € 7% 2,88%
    Pfizer 30,000 € 7% 2,88%
    Regeneron 30,000 € 7% 2,88%
    Roche 30,000 € 7% 2,88%
    Sanofi Genzyme 30,000 € 7% 2,88%

    EFA project programme:
    Atopic Eczema Consensus Europe
    - Abbvie 41,433 € 5% 3,98%
    - Leo Pharma 41,433 € 5% 3,98%
    - Sanofi/Regeneron 41,433 € 5% 3,98%

    BREATHE Coalition
    - Astra Zeneca 29,920 € 4% 2,87%
    - Boehringer Ingelheim 29,920 € 4% 2,87%
    - Chiesi 29,920 € 4% 2,87%
    - GSK 29,920 € 4% 2,87%
    - Roche 29,920 € 4% 2,87%
    - Breathe Coalition Deferred Income from 2020 5,000 € 1% 0,48%

    Capacity Building
    - Astra Zeneca 38,225 € 5% 3,67%
    - Chiesi 25,483 € 3% 2,45%
    - Novartis 25,483 € 3% 2,45%
    - Deferred income from 2020 5,000 € 1% 0,48%

    DIG_IT
    - Astra Zeneca 76,371 € 9% 7,33%
    - Chiesi 76,371 € 9% 7,33%
    - MSD 76,371 € 9% 7,33%
    - OM Pharma 76,371 € 9% 7,33%
    - Roche 76,371 € 9% 7,33%
    Deferred Income from 2020 25,000 € 3% 2,40%

    Interest Group
    - Chiesi 15,106 € 2% 1,45%
    - GSK 15,106 € 2% 1,45%
    - Sanofi/Regeneron 15,106 € 2% 1,45%
    Deferred Income from 2020 5,000 € 1% 0,48%

    Deferred income 2021 to EFA Projects 2022 -169.076

  • EU Structures

    Groups (European Commission)

    Zero Pollution Stakeholder Platform#E03790#https://ec.europa.eu/transparency/expert-groups-register/screen/expert-groups/consult?groupID=3790 #Member #C#Civil society

    Groups (European Parliament)

    European Parliament Interest Group on Allergy and Asthma (informal group: https://allergyasthmaparliament.eu/)
    European Parliament MEP Lung Health Group (informal group: https://www.ersnet.org/advocacy/mep-lung-health-group/)

    Other activities

    Eligible organisation to the European Medicines Agency (EMA)
    NGO Stakeholder to the European Food Safety Authority (EFSA)
    Stakeholder to the European Chemicals Agency (ECHA)
    Observer organisation to the Codex Alimentarius Commission (FAO/WHO)

  • Meetings

    Meetings

    1 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't publish information about such meetings. All information below comes from European Commission web pages.

Download this datacard